Skip to main content
SpringerLink
Log in

Androgenetische Alopezie individuell behandeln

Evidenzbasiertes Management

  • cme fortbildung
  • Published:
ästhetische dermatologie & kosmetologie Aims and scope

Zusammenfassung

Die androgenetische Alopezie (AGA), eine der häufigsten Ursachen für Haarausfall, führt bei vielen Betroffenen unabhängig von Ausprägung, Alter oder Geschlecht zu einem enormen psychosozialen Leidensdruck und einer nachhaltigen Beeinflussung der Lebensqualität. Die differenzierte und standardisierte Diagnostik der AGA stellt bei Frauen, Männern und Jugendlichen eine essenzielle Grundlage für die Entwicklung eines erfolgreichen therapeutischen Konzepts dar. Behandlungsoptionen reichen von topischen und systemischen Pharmazeutika über kosmetische Produkte, Nutrikosmetika, Haartransplantationen bis hin zu ästhetisch korrektiven Ansätzen. Es obliegt der gemeinsamen Entscheidung von Arzt und Patient, die beste individuell adaptierte Therapie nach Abwägung von zu erwartendem Ergebnis, Umsetzbarkeit und Compliance auszuwählen. Ein notwendiges interdisziplinäres Vorgehen erfolgt individuell, abhängig von weiteren Befunden genauso wie die Entwicklung von Coping-Strategien und die Entscheidung für psychologische Unterstützung. Professionelle Behandlung und empfindsamer Umgang mit der emotional belastenden Situation helfen, eine Vertrauensbasis zwischen Arzt und Patienten zu schaffen, um höchstmögliche Zufriedenheit und Compliance der Patienten zu erzielen. Die S1-Leitlinie zur Diagnostik und die S3-Leitlinie zu therapeutischen Empfehlungen der AGA bieten dem behandelnden Arzt wichtige Orientierungshilfen für ein erfolgreiches, evidenzbasiertes Management betroffener Patienten.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2
3

Literatur

  1. Blume-Peytavi U, Blumeyer A, Tosti A et al (2011) S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol 164:5–15

    Article  PubMed  CAS  Google Scholar 

  2. Olsen EA (2008) Female pattern hair loss. In: Blume-Peytavi U, Tosti A, Whiting DA et al (Hrsg) Hair growth and disorders. Springer, Berlin Heidelberg New York Tokio, S 171–186

    Chapter  Google Scholar 

  3. Cash TF, Price VH, Savin RC (1993) Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol 29(4):568–575

    Article  PubMed  CAS  Google Scholar 

  4. Hadshiew IM, Foitzik K, Arck PC, Paus R (2004) Burden of hair loss: stress and the underestimated psychosocial impact of telogen effluvium and androgenetic alopecia. Invest Dermatol 123(3):455–457

    Article  CAS  Google Scholar 

  5. Cartwright T, Endean N, Porter A (2009) Illness perceptions, coping and quality of life in patients with alopecia. Br J Dermatol 160(5):1034–1039

    Article  PubMed  CAS  Google Scholar 

  6. Hunt N, McHale S (2005) The psychological impact of alopecia. BMJ 331:951–953

    Article  PubMed  PubMed Central  Google Scholar 

  7. Nardi AE (2005) Psychological impact of alopecia: alopecia may lead to social anxiety. BMJ 331(7524):1084

    Article  PubMed  PubMed Central  Google Scholar 

  8. Messenger A (2008) Androgenetic alopecia in men. In: Blume-Peytavi U, Tosti A, Whiting DA et al (Hrsg) Hair growth and disorders. Springer, Berlin Heidelberg New York Tokio, S 159–170

    Chapter  Google Scholar 

  9. Blume-Peytavi U, Vogt A (2011) Current standards in the diagnostics and therapy of hair diseases - hair consultation. J Dtsch Dermatol Ges 9:394–412

    PubMed  Google Scholar 

  10. Blumeyer A, Tosti A, Messenger A et al (2011) Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges 9:S1–S57

    Article  PubMed  Google Scholar 

  11. Birch MP, Messenger AG (2001) Genetic factors predispose to balding and non-balding in men. Eur J Dermatol 11(4):309–314

    PubMed  CAS  Google Scholar 

  12. Nyholt DR, Gillespie NA, Heath AC, Martin NG (2003) Genetic basis of male pattern baldness. J Invest Dermatol 121(6):1561–1564

    Article  PubMed  Google Scholar 

  13. Heilmann S, Brockschmidt FF, Hillmer AM et al (2013) Evidence for a polygenic contribution to androgenetic alopecia. Br J Dermatol 169(4):927–930

    PubMed  CAS  Google Scholar 

  14. Heilmann S, Kiefer AK, Fricker N et al (2013) Androgenetic alopecia: identification of four genetic risk loci and evidence for the contribution of WNT signaling to its etiology. J Invest Dermatol 133(6):1489–1496

    Article  PubMed  CAS  Google Scholar 

  15. Hillmer AM, Hanneken S, Ritzmann S et al (2005) Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Am J Hum Genet 77:140–148

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Hillmer AM, Brockschmidt FF, Hanneken S et al (2008) Susceptibility variants for male-pattern baldness on chromosome 20p11. Nat Genet 40:1279–1281

    Article  PubMed  CAS  Google Scholar 

  17. Redler S, Dobson K, Drichel D et al (2013) Investigation of six novel susceptibility loci for male androgenetic alopecia in women with female pattern hair loss. J Dermatol Sci 72(2):186–188

    Article  PubMed  CAS  Google Scholar 

  18. Gan DC, Sinclair RD (2005) Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc 10(3):184–189

    Article  PubMed  Google Scholar 

  19. Norwood OT (1975) Male pattern baldness: classification and incidence. South Med J 68:1359–1365

    Article  PubMed  CAS  Google Scholar 

  20. Olsen EA (2004) Pattern hair loss in men and women. In: Olsen EA (Hrsg) Hair disorders: diagnosis and treatment. McGraw-Hill, New York

    Google Scholar 

  21. Ludwig E (1977) Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 97:247–254

    Article  PubMed  CAS  Google Scholar 

  22. Hillmann K, Blume-Peytavi U (2009) Diagnosis of hair disorders. Semin Cutan Med Surg 28(1):33–38

    Article  PubMed  CAS  Google Scholar 

  23. Blume-Peytavi U, Hillmann K, Dietz E et al (2011) A randomized, singleblind trial of 5 % minoxidil foam once daily versus 2 % minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol 65(6):1126–1134

    Article  PubMed  CAS  Google Scholar 

  24. Poot F (2009) Doctor-patient relations in dermatology: obligations and rights for mutual satisfaction. Eur J Acad Dermatol Venereol 23:1233–1239

    Article  CAS  Google Scholar 

  25. Tu HY et al (2011) Finasteride-induced secondary infertility associated with sperm DNA damage. Fertil Steril 95(6):2125.e13–e4

    Google Scholar 

  26. Chiba K et al (2011) Finasteride-associated male infertility. Fertil Steril 95(5):1786.e9–11

    Google Scholar 

  27. Glina S et al (2004) Finasteride-associated male infertility. Rev Hosp Clin Fac Med Sao Paulo 59(4):203–205

    Article  PubMed  Google Scholar 

  28. Shenoy NK, Prabhakar SM (2010) Finasteride and male breast cancer: does the MHRA report show a link? J Cutan Aesthet Surg 3(2):102–105

    PubMed  PubMed Central  Google Scholar 

  29. Mella JM et al (2010) Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol 146(10):1141–1150

    PubMed  Google Scholar 

  30. Jung JY, Yeon JH, Choi JW, Kwon SH, Kim BJ, Youn SW, Park KC, Huh CH (2014), Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol doi: 10.1111/ijd.12060. [Epub ahead of print]

  31. Vexiau P, Chaspoux C, Boudou P et al (2002) Effects of minoxidil 2 % vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol 146:992–999

    Article  PubMed  CAS  Google Scholar 

  32. Colombe Michelet JF, Bernard BA (2008) Prostanoid receptors in anagen human hair follicles. Exp Dermatol 17(1):63–72

    Google Scholar 

  33. Demitsu T, Manabe M, Harima N et al (2001) Hypertrichosis induced by latanoprost. J Am Acad Dermatol 44(4):721–723

    Article  PubMed  CAS  Google Scholar 

  34. Blume-Peytavi U, Lonnfors S, Hillmann K, Garcia Bartels N (2012) A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1 % on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol 66(5):794–800

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Dermatologie, Venerologie und Allergologie, Clinical Research Center for Hair and Skin Science, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland

    Ulrike Blume-Peytavi &  Annika Vogt

Authors
  1. Ulrike Blume-Peytavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annika Vogt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrike Blume-Peytavi.

Additional information

Interessenkonflikt

U. Blume-Peytavi: Beratungs- und Vortragshonorare von Johnson & Johnson, Galderma, Pierre Fabre, Replicel. A. Vogt gibt an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blume-Peytavi, U., Vogt, A. Androgenetische Alopezie individuell behandeln. ästhet dermatol kosmetol 6, 27–39 (2014). https://doi.org/10.1007/s12634-014-0866-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12634-014-0866-0

Schlüsselwörter

Search

Navigation